Semigolovskiĭ N Iu
Anesteziol Reanimatol. 1998 Mar-Apr(2):56-9.
A total of 620 patients with acute myocardial infarction were followed up in order to assess the efficacy of antihypoxants as a component of intensive care. 385 of these patients, divided into groups of 20-40 subjects, were administered one of 12 antihypoxants or sessions of hyperbaric oxygenation during the acute period of the disease, the rest were treated traditionally. Analysis of clinical, laboratory, and prognostic values showed the highest protective effect of amtizol, lithium hydroxybutyrate, piracetam, and ubiquinone. Cytochrome C, riboxine, mildronate, and olifen were somewhat less active, and solcoseryl, bemitil, trimethasidine, and aspisol were the least effective. The protective potentialities of standard sessions of hyperbaric oxygenation were virtually null. The author proposes a parameter D, reflecting the difference between actual and predicted mortality, and the rating (score) system for assessing the routine laboratory diagnostic tests to be used together with the known criteria for evaluation of the protective effects of antihypoxants in patients with acute myocardial infarction.
共有620例急性心肌梗死患者接受随访,以评估抗缺氧剂作为重症监护组成部分的疗效。其中385例患者在疾病急性期被分成20至40人的小组,接受12种抗缺氧剂之一或高压氧治疗,其余患者接受传统治疗。对临床、实验室和预后价值的分析表明,氨替唑、羟丁酸锂、吡拉西坦和泛醌具有最高的保护作用。细胞色素C、核糖核酸、米多君和奥立芬的活性稍低,而索高捷疗、贝米替尔、曲美他嗪和阿匹索尔效果最差。标准高压氧治疗的保护潜力几乎为零。作者提出了一个参数D,反映实际死亡率与预测死亡率之间的差异,以及一个评分系统,用于评估常规实验室诊断测试,并与评估急性心肌梗死患者抗缺氧剂保护作用的已知标准一起使用。